Report Type: Industry Trends
Report Category: Regulatory Insights
Report Subcategory: Orphan Drug Designation
Date: February 2022
Orphan Drug Designation (ODD): Drugs, Companies, News, Deals, Patents, Drug Sales & Forecast, Future Events, DMF, Manufacturing
Orphan Drug Designation (ODD) provides market exclusivity for the rare indication drugs. ODD criteria varies by country.
Regulatory authorities provides ODD are US FDA, Europe EMEA,Japan PMDA, China NMPA, Australia TGA, South Korea KFDA, Brazil ANVISA, Mexico COFEPRIS, France ANSM, Spain AEMPS and etc.
Email : email@example.com or Call : +1 (732) 526 1166
Get The Latest Updates